Cabozantinib Inhibits Growth of Androgen-Sensitive and Castration-Resistant Prostate Cancer and Affects Bone Remodeling

Cabozantinib is an inhibitor of multiple receptor tyrosine kinases, including MET and VEGFR2. In a phase II clinical trial in advanced prostate cancer (PCa), cabozantinib treatment improved bone scans in 68% of evaluable patients. Our studies aimed to determine the expression of cabozantinib targets...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Nguyen, Holly M., Ruppender, Nazanin, Zhang, Xiaotun, Brown, Lisha G., Gross, Ted S., Morrissey, Colm, Gulati, Roman, Vessella, Robert L., Schimmoller, Frauke, Aftab, Dana T., Corey, Eva
Формат: Artigo
Язык:Inglês
Опубликовано: Public Library of Science 2013
Предметы:
Research Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3808282/
https://ncbi.nlm.nih.gov/pubmed/24205338
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0078881
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы